Like Shark Attack and the Lottery, Unconscious Bias Influences Cancer Screening

Doctors with personal experience of cancer are more likely to act against established guidelines to recommend that low-risk women receive ovarian cancer screening.
17-Aug-2018 12:15 PM EDT Add to Favorites

No single test identifies all ROS1+ lung cancer patients

University of Colorado Cancer Center study shows that common laboratory tests used to determine ROS1 status may return false-negative results, meaning that some patients who could benefit from ROS1-directed therapy may be slipping through the cracks.
8-Aug-2018 11:05 AM EDT Add to Favorites

Ivosidenib earns FDA approval against IDH1+ acute myeloid leukemia

Clinical trials at CU Cancer Center and elsewhere result in FDA approval of the drug ivosidenib for the treatment of adult patients with IDH1+ AML.
30-Jul-2018 10:05 AM EDT Add to Favorites

Brain Metastases Common and Difficult to Treat in ROS1 Lung Cancer

Brain metastases were found to be fairly common in stage IV ROS1-positive cancers and in 47 percent of ROS1 patients, the brain was the first and only site of progression.
10-Jul-2018 12:05 PM EDT Add to Favorites

Updated ALEX Trial Results Show Alectinib Further Outpacing Crizotinib in Treatment Naive ALK+ NSCLC

Dpdated data further consolidate alectinib as the standard-of-care for first-line treatment of ALK+ non-small cell lung cancer.
3-Jun-2018 7:05 AM EDT Add to Favorites

As Colorectal Cancer Rises in Young People, New Guidelines Recommend Screening Start at 45

Study published today the journal Cancer recommends colorectal cancer screening start at age 45, five years younger than currently recommended for both men and women of all races and ethnicities.
30-May-2018 11:05 AM EDT Add to Favorites

Ice Cream Funds Research Showing New Strategy Against Thyroid Cancer

University of Colorado Cancer Center study shows that stereotactic body radiation (SBRT) may be better against anaplastic thyroid cancer, and with fewer side effects.
21-May-2018 11:05 AM EDT Add to Favorites

Largest-Ever Study of Thyroid Cancer Genetics Finds New Mutations, Suggests Immunotherapy

CU researchers mine data of 583 patient samples of advanced differentiated thyroid cancer and 196 anaplastic thyroid cancers, showing genetic alterations, and "high mutation burden" that is an FDA-approved marker for immunotherapy.
26-Apr-2018 1:05 PM EDT Add to Favorites

see all news